Moreover, the combined use of ibrutinib and nutlin-3, both able to reduce the levels of c-MYC in independent manner, could represent a new pharmacological strategy to escape the resistance to inhibitors of BCR signaling in B cell non-Hodgkin lymphoma (B-NHL) models expressing elevated levels of c-MYC [30]. Here, MYC is linked to B-cell non-Hodgkin lymphoma.